ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 7, 2020

9:00AM-11:00AM: Abstract Number: 0584

Total Cost of Care for Patients with Rheumatoid Arthritis

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0924

Towards Systemic Sclerosis Rehabilitation via Videogames

Systemic Sclerosis & Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 0547

Transgender Patients in the Rheumatology Setting

Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0816

Treat-to-target Strategy in Patients with Rheumatoid Arthritis in Daily Clinical Practice -still Underused, but Superior to Routine Care: A Propensity Score Matched Analysis from the ATTRA Registry

RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

9:00AM-11:00AM: Abstract Number: 0855

Treatment of SLE with or Without Nephritis with the Immunoproteasome Inhibitor KZR-616: Updated Results of the MISSION Study

SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0813

Treatment Outcomes in Patients with Seropositive versus Seronegative Rheumatoid Arthritis in Czech Registry ATTRA Treated with JAK Inhibitors

RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

9:00AM-11:00AM: Abstract Number: 0665

Trends in Immunomodulation/pegloticase Co-therapy from 2015-2019: A Claims Database Study

Metabolic & Crystal Arthropathies Poster

9:00AM-11:00AM: Abstract Number: 0572

Two-year Cost-effectiveness Between Two Gradual Tapering Strategies in Rheumatoid Arthritis: Cost-utility Analysis of the TARA Trial

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0764

Uncovering Novel Biomarkers for Rheumatoid Arthritis from Feature Selection and Machine Learning Approaches on Synovium and Blood Gene Expression Data

RA – Diagnosis, Manifestations, & Outcomes Poster II: Biomarkers

9:00AM-11:00AM: Abstract Number: 0784

Upregulation of Tyro3TK on CD14+CD16- Monocytes Promotes Osteoclast Formation in Rheumatoid Arthritis

RA – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0817

Uptake of Janus Kinase Inhibitors for Management of Rheumatoid Arthritis in Australia

RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

9:00AM-11:00AM: Abstract Number: 0664

Uric Acid Level Is Associated with Severity of Heart Failure with Preserved Ejection Fraction

Metabolic & Crystal Arthropathies Poster

9:00AM-11:00AM: Abstract Number: 0872

Usage of Corticosteroids and Hospitalisation Duration in Adult Patients with Systemic Lupus Erythematosus (SLE) in Latvia

SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0643

Use of Biologic Treatment and Risk to Be Admitted for COVID-19 Infection

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0555

Utilization and Adherence Among Infliximab Biosimilar Initiators in a U.S. National Commercial Insurance Database

Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].